Suppr超能文献

钙拮抗剂与高血压

Calcium antagonists and hypertension.

作者信息

Nayler W G, Dillon J S, Sturrock W J

机构信息

Department of Medicine, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australia.

出版信息

Clin Exp Pharmacol Physiol. 1988 Feb;15(2):93-103. doi: 10.1111/j.1440-1681.1988.tb01050.x.

Abstract
  1. Calcium antagonists, including verapamil, are now used widely in the management of patients with hypertension. 2. Six weeks of chronic therapy with verapamil (50 mg/kg per day, orally) to produce a plasma level of 80-100 ng/ml in Sprague-Dawley rats depletes cardiac noradrenaline (NA) without apparently causing beta 1 adrenoceptor 'up' regulation. 3. The effect of verapamil on cardiac NA is rapidly reversed upon verapamil withdrawal. 4. Chronic therapy with nisoldipine (100 mg/kg per day, orally) had no effect on cardiac NA. 5. Verapamil (50 mg/kg per day, orally) and nisoldipine (100 mg/kg per day, orally) therapy for 6 weeks prevented the time-dependent increase in systolic blood pressure in SHR rats. 6. Binding studies with (-)[3H]-D888 (desmethoxyverapamil) indicated that the affinity of the phenylalkylamine binding sites is higher in hearts of SHR relative to hearts from age-matched (25 weeks) WKY and SD, without any change in density.
摘要
  1. 包括维拉帕米在内的钙拮抗剂目前广泛用于高血压患者的治疗。2. 用维拉帕米(每天50毫克/千克,口服)对斯普拉格-道利大鼠进行六周的慢性治疗,使其血浆水平达到80 - 100纳克/毫升,可耗尽心脏去甲肾上腺素(NA),且未明显引起β1肾上腺素能受体的“上调”。3. 停用维拉帕米后,其对心脏NA的作用迅速逆转。4. 用尼索地平(每天100毫克/千克,口服)进行慢性治疗对心脏NA无影响。5. 用维拉帕米(每天50毫克/千克,口服)和尼索地平(每天100毫克/千克,口服)治疗6周可防止自发性高血压大鼠(SHR)收缩压随时间的升高。6. 用(-)-[3H]-D888(去甲氧基维拉帕米)进行的结合研究表明,相对于年龄匹配(25周)的WKY和SD大鼠的心脏,SHR大鼠心脏中苯烷基胺结合位点的亲和力更高,而密度无任何变化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验